Multi-institutional Study of Osimertinib Dose-Optimization in Non-Small Cell Lung Cancer Patients with EGFR Activating Mutation Aged 70 Years or Older (‘MONEY’ Trial)
JAPANESE JOURNAL OF CLINICAL ONCOLOGY（2024）
关键词
osimertinib,dose-optimization,non-small cell lung cancer,epidermal growth factor receptor activating mutation,regression discontinuity design
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要